Clinical Trials

474 enrolled

Prostatic Neoplasms

NCT07145177 2026-06-01

177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

Prostatic Neoplasms

NCT06574880 2026-05-26

STARLiT

Phase 1/2 Recruiting

45 enrolled

Phase NA Not yet recruiting

Prostatic Neoplasms

NCT07587814 2026-05-14

COCORIVO

100 enrolled

Carcinoma, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT06852820 2026-05-08

68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)

Phase 2 Not yet recruiting

10 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT07025512 2026-05-08

177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia

Phase 2 Withdrawn

Classical hematology

Cytopenia, Anemia, Thrombocytopenia

NCT07550517 2026-04-24

PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT

60 enrolled

High-Risk Localized Prostate Cancer

NCT07219147 2026-04-20

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms

NCT05766371 2026-04-17

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

48 enrolled

Prostatic Neoplasms

NCT05113537 2026-04-13

UPLIFT

Phase 1/2 Recruiting

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT06303713 2026-04-08

LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer

37 enrolled

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT05079698 2026-04-07

A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer

29 enrolled

Prostatic Neoplasms

NCT07054346 2026-04-01

LUTACT

45 enrolled

Phase 1 Active not recruiting

Disease, Prostatic Neoplasms

NCT04886986 2026-03-31

Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer

20 enrolled

Prostatic Neoplasms

NCT06389097 2026-03-30

(SEEtoTREAT)

Recruiting

80 enrolled

Prostatic Neoplasms

NCT06526299 2026-03-24

Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease

51 enrolled

Prostatic Neoplasms

NCT06288113 2026-03-13

Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

40 enrolled

Prostatic Neoplasms

NCT06216249 2026-03-10

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

90 enrolled

Prostatic Neoplasms

NCT04443062 2026-02-27

Bullseye

Phase 2 Completed

58 enrolled

Phase 3 Not yet recruiting

Prostatic Neoplasms

NCT06959433 2026-02-27

Lu-177 PSMA Treatment in Cell Renal Carcinoma

20 enrolled

Phase 2 Active not recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT06964958 2026-02-24

LASER

24 enrolled

Carcinoma, Renal Cell, Kidney Neoplasms

NCT06145633 2026-01-28

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

15 enrolled

Prostatic Neoplasms

NCT06866938 2026-01-06

ReaLuP

58 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT05162573 2025-12-10

PROQURE-1

Phase 1 Completed

14 enrolled

Prostatic Neoplasms

NCT05613894 2025-10-31

CaboLu

33 enrolled

Phase 3 Not yet recruiting

Metastatic Castration-resistant Prostate Cancer

NCT07200830 2025-10-01

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

1,524 enrolled

Prostatic Neoplasms

NCT06320067 2025-09-26

STAMPEDE2

Phase 3 Recruiting

3,360 enrolled

Phase 1/2 Active not recruiting

Prostate Cancer Metastatic

NCT03042468 2025-09-17

Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC

50 enrolled 19 charts

Prostatic Neoplasms

NCT06200103 2025-09-11

Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

236 enrolled

Prostatic Neoplasms

NCT06943495 2025-09-09

PRODIGY-2

60 enrolled

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

NCT06738303 2025-08-27

CATCH-177

44 enrolled

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04343885 2025-07-11

UpFrontPSMA

130 enrolled

Metastatic Hormone Naive Prostate Cancer

NCT06972628 2025-05-15

Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT05340374 2025-04-06

LuCAB

35 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT06461689 2025-03-04

PROLUT

Completed

80 enrolled

Prostatic Neoplasms

NCT03805594 2025-02-25

177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1 Completed

43 enrolled 20 charts

Prostatic Neoplasms

NCT06449781 2025-02-10

PSMA-ADJUVO

200 enrolled

Prostatic Neoplasms

NCT06496581 2024-12-20

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

Phase 3 Recruiting

500 enrolled

Phase 1/2 Active not recruiting

Genital Diseases, Male, Prostatic Diseases

NCT04430192 2024-11-08

LuTectomy

20 enrolled

Prostatic Neoplasms

NCT06329830 2024-09-19

LUNAAR

Phase 1/2 Withdrawn

Prostatic Neoplasms

NCT05150236 2023-12-15

ANZUP2001

Phase 2 Unknown

93 enrolled

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT03392428 2022-06-13

TheraP

Phase 2 Completed

201 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT03545165 2021-08-24

177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC

Phase 1/2 Terminated

6 enrolled 24 charts

Prostatic Neoplasms

NCT03828838 2019-11-14

Lutetium-177-PSMA-617 in Low Volume Metastatic Prostate Cancer

Phase 1/2 Completed

10 enrolled